InflaRx NV (MEX:IFRXN) Cyclically Adjusted PS Ratio: (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:IFRXN InflaRx NV MEX:IFRXN
35 GF Score
Price MXN22.00
! 2 Warning Signs
View Full Analysis

What is InflaRx NV Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


InflaRx NV  (MEX:IFRXN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


InflaRx NV Cyclically Adjusted PS Ratio Related Terms


InflaRx NV Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for InflaRx NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InflaRx NV Cyclically Adjusted PS Ratio Chart

InflaRx NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 305.42

InflaRx NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 305.42 0.00 0.00

MEX:IFRXN vs VRXA, TTRX, IRD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, InflaRx NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Cyclically Adjusted PS Ratio falls into.


MEX:IFRXN
35GF Score
InflaRx NV MEX:IFRXN
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InflaRx NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

InflaRx NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, InflaRx NV's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/131.3638*131.3638
=0.000

Current CPI (Jun. 2026) = 131.3638.

InflaRx NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 101.017 0.000
201612 0.000 101.217 0.000
201703 0.000 101.417 0.000
201706 0.000 102.117 0.000
201709 0.000 102.717 0.000
201712 0.000 102.617 0.000
201803 0.000 102.917 0.000
201806 0.000 104.017 0.000
201809 0.000 104.718 0.000
201812 0.000 104.217 0.000
201903 0.000 104.217 0.000
201906 0.000 105.718 0.000
201909 0.000 106.018 0.000
201912 0.000 105.818 0.000
202003 0.000 105.718 0.000
202006 0.000 106.618 0.000
202009 0.000 105.818 0.000
202012 0.000 105.518 0.000
202103 0.000 107.518 0.000
202106 0.000 108.486 0.000
202109 0.000 109.435 0.000
202112 0.000 110.384 0.000
202203 0.000 113.968 0.000
202206 0.000 115.760 0.000
202209 0.000 118.818 0.000
202212 0.000 119.345 0.000
202303 0.000 122.402 0.000
202306 0.000 123.140 0.000
202309 0.019 124.195 0.020
202312 0.001 123.773 0.001
202403 0.011 125.038 0.012
202406 0.002 125.882 0.002
202409 0.046 126.198 0.048
202412 0.000 127.041 0.000
202503 0.000 127.779 0.000
202506 0.013 128.412 0.013
202509 0.008 129.255 0.008
202512 -0.010 129.361 -0.010
202603 0.000 131.258 0.000
202606 0.000 131.364 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


InflaRx NV Business Description

Other Exchanges IFRX:USAIF0:Germany
Address Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
35GF Score

Get the complete analysis for MEX:IFRXN

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN22.00
Price